1. Home
  2. BANL vs AKTX Comparison

BANL vs AKTX Comparison

Compare BANL & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BANL

CBL International Limited

BUY

Current Price

$3.28

Market Cap

19.0M

Sector

Energy

ML Signal

BUY

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$7.84

Market Cap

15.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANL
AKTX
Founded
2015
N/A
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.0M
15.4M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
BANL
AKTX
Price
$3.28
$7.84
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $25.50
AVG Volume (30 Days)
12.9K
★ 41.5K
Earning Date
08-18-2026
11-12-2026
Dividend Yield
★ 3.26%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$0.12
52 Week High
$16.40
$29.32

Technical Indicators

Market Signals
Indicator
BANL
AKTX
Relative Strength Index (RSI) 33.49 46.40
Support Level $0.36 $6.76
Resistance Level $5.18 $10.98
Average True Range (ATR) 0.35 0.94
MACD 0.05 0.02
Stochastic Oscillator 27.50 48.33

Price Performance

Historical Comparison
BANL
AKTX

About BANL CBL International Limited

CBL International Ltd is a marine fuel logistics company that provides a one-stop solution for vessel refueling. In the bunkering industry, it is referred to as a bunkering facilitator. It facilitates vessel refueling between ship operators and local physical distributors/traders by purchasing marine fuel, including fossil fuel and alternative fuel, from its suppliers and arranging for the suppliers to deliver the fuel to the customers. The company's customer base comprises container liners, bulk carriers, and tankers. Geographically, the company generates a majority of its revenue from China, followed by Hong Kong, Malaysia, Singapore, South Korea, and other regions.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: